A Phase 3 interventional study of Avelumab and Oxaliplatin in Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 200 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-09.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing avelumab in Neoplasm Metastasis — 1 open to participants now, 3 under way, none of them phase 3. avelumab · Neoplasm Metastasis.
Among the 10 studies testing avelumab in Neoplasm Metastasis, this one is the 2nd largest by enrollment, is the only one that started in 2015, is the only one in phase 3, and was the 2nd registered.
4,045 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.
Browse Neoplasm Metastasis studies →1 of the 10 studies testing avelumab in Neoplasm Metastasis is open now, in 1 country. Recruiting first, the newest first:
Institut Bergonié · Sites in France
Ages 18+
By country, each count listing its studies:
avelumab: first FDA approval 2017 (BAVENCIO), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 1
First in 2014; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 499 is above the median of 50 across 3,270 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 46 across the 10 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 9 most frequent:
This study is registered under EMD Serono Research & Development Institute, Inc., one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany: none open now, none under way, none of them phase 3. Of 21 finished, 11 (52%) have results posted.
Among the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2015, is the only one in phase 3, and was the 17th registered.
Merck KGaA, Darmstadt, Germany’s Neoplasm Metastasis studies by the year they started, since 2005.
2 of the studies testing avelumab in Neoplasm Metastasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03391479University Health Network, TorontoA Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy | 2026-12-31 |
| NCT04792073Memorial Sloan Kettering Cancer CenterStudy of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing avelumab in Neoplasm Metastasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 21 in Neoplasm Metastasis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Maintenance Phase, participants continued the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5FU/LV or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Participants who were not deemed eligible to receive chemotherapy at the dose and schedule specified above received BSC alone once every 3 weeks. BSC was defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and was based on Investigator's discretion.
Drug: Oxaliplatin · Drug: 5-Fluorouracil · Drug: Leucovorin · Drug: Capecitabine · Other: Best supportive care
In Maintenance phase, participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligrams per kilogram (mg/kg) once every 2-week treatment cycle until progressive disease or unacceptable toxicity or discontinuation.
Drug: Avelumab
Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
Also known as: MSB0010718C, Anti PD-L1
Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.
Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
Overall Survival (OS)
Overall Survival was defined as the time from randomization to the date of death due to any cause. For participants who were still alive at the time of data analysis or who were lost to follow-up, OS time was censored at the date of last contact. OS was measured using Kaplan-Meier (KM) estimates.
Time frame: From randomization into maintenance phase up to 1276 days
Progression Free Survival (PFS) by Independent Review Committee (IRC)
The PFS time was defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause (whichever occurs first). PFS was assessed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as per IRC. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Time frame: From randomization into maintenance phase up to 1276 days
Best Overall Response (BOR) by Investigator Assessment
BOR was determined by RECIST v1.1 per Investigator assessment and defined as best-confirmed response of any of following: complete response (CR), partial response (PR), stable disease (SD) and PD recorded from date of randomization until disease progression or recurrence. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in SLD of all lesions. SD: Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD is defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or appearance of 1 or more new lesions. PR or CR confirmed at a subsequent tumor assessment, not sooner than 5 weeks after initial documentation or at an assessment later than the next assessment after the initial documentation of PR or CR. SD confirmed at least 6 weeks after randomization. Confirmed PD equal to progression \<=2 weeks after date of randomization.
Time frame: From randomization into maintenance phase up to 1276 days
Objective Response Rate (ORR) by Investigator Assessment
The ORR defined as the percentage of all randomized participants with a confirmed best overall response (BOR) of partial response (PR),or complete response (CR) according to RECIST v1.1 and as per Investigator assessment. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions.
Time frame: From randomization into maintenance phase up to 1276 days
Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire Through Composite Index Score up to Safety Follow-up (Up to 152.3 Weeks)
EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall composite health state index score, with scores ranging from -0.594 to 1. A higher score indicates better health state.
Time frame: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Change From Baseline in European Quality of Life 5-dimensions Health Outcome Questionnaire Through Visual Analogue Scale up to Safety Follow-up (Up to 152.3 Weeks)
EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.
Time frame: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score up to Safety Follow-up (Up to 152.3 Weeks)
European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact. The EORTC QLQ-C30 GHS/QoL score ranges from 0 to 100; High score indicates better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.
Time frame: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) Questionnaire Scores up to Safety Follow-up (Up to 152.3 Weeks)
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) supplements the EORTC QLQ-C30 to assess symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, pain, reflux symptom, dietary restrictions, and anxiety) and 4 single items (dry mouth, hair loss, taste, body image). Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.
Time frame: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Maintenance Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.
Time frame: From randomization into maintenance phase up to 1276 days
Maintenance Phase: Number of Participants With Grade Change From Baseline to Worst On-Treatment Grade 4 Hematology Values
Blood samples were collected for the analysis of following hematology parameters: lymphocyte count, neutrophil count, white blood cells, platelet count, lipase, serum amylase, creatinine phosphokinase and creatinine. The hematology parameters were graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case (Grade 4) post Baseline is presented. Only those participants with increase to grade 4 have been presented.
Time frame: From baseline up to 1276 days
Maintenance Phase: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
Vital signs assessment included Systolic blood pressure (SBP), Diastolic blood pressure (DBP) and Pulse Rate (PR). Number of Participants with any potentially clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator.
Time frame: From randomization into maintenance phase up to 1276 days
Maintenance Phase: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
ECG parameters included heart rate, pulse rate intervals, QRS interval, QT interval corrected based on Fridericia's formula (QTcF) intervals and QTcB intervals. Clinical significance was determined by the investigator. Number of participants with potentially clinically significant ECG abnormalities were reported.
Time frame: From randomization into maintenance phase up to 1276 days
Maintenance Phase: Number of Participants With Shift in Eastern Cooperative Oncology Group (ECOG) Performance Status Score to 1 or Higher Than 1
ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 5, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair, Grade 5 = Death. Number of participants with shift in ECOG PS Score to 1 or Higher Than 1 were reported.
Time frame: From randomization into maintenance phase up to 1276 days
| Milestone | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Started | 250 | 249 |
| Safety-maintenance analysis set | 238 | 243 |
| Completed | 250 | 249 |
| Not completed | 0 | 0 |
Overall Survival was defined as the time from randomization to the date of death due to any cause. For participants who were still alive at the time of data analysis or who were lost to follow-up, OS time was censored at the date of last contact. OS was measured using Kaplan-Meier (KM) estimates.
| months | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Overall Survival (OS) | 10.9 (9.6 to 12.4) | 10.4 (9.1 to 12.0) |
The PFS time was defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause (whichever occurs first). PFS was assessed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as per IRC. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
| months | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Progression Free Survival (PFS) by Independent Review Committee (IRC) | 4.4 (4.0 to 5.5) | 3.2 (2.8 to 4.1) |
BOR was determined by RECIST v1.1 per Investigator assessment and defined as best-confirmed response of any of following: complete response (CR), partial response (PR), stable disease (SD) and PD recorded from date of randomization until disease progression or recurrence. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in SLD of all lesions. SD: Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD is defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or appearance of 1 or more new lesions. PR or CR confirmed at a subsequent tumor assessment, not sooner than 5 weeks after initial documentation or at an assessment later than the next assessment after the initial documentation of PR or CR. SD confirmed at least 6 weeks after randomization. Confirmed PD equal to progression \<=2 weeks after date of randomization.
| Participants | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Complete response | 5 | 8 |
| Partial response | 31 | 25 |
| Stable disease | 117 | 92 |
| Noncomplete response/non progressive disease | 11 | 10 |
| Progressive disease | 58 | 85 |
| Non evaluable | 28 | 29 |
The ORR defined as the percentage of all randomized participants with a confirmed best overall response (BOR) of partial response (PR),or complete response (CR) according to RECIST v1.1 and as per Investigator assessment. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions.
| percentage of participants | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Objective Response Rate (ORR) by Investigator Assessment | 14.4 (10.3 to 19.4) | 13.3 (9.3 to 18.1) |
EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall composite health state index score, with scores ranging from -0.594 to 1. A higher score indicates better health state.
| Units on Scale | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Week 3/4 | -0.002 ± 0.1242 | 0.004 ± 0.1610 |
| Week 7 | -0.032 ± 0.1644 | -0.009 ± 0.1588 |
| Week 13 | -0.053 ± 0.1733 | -0.017 ± 0.1599 |
| Week 19 | -0.039 ± 0.1934 | -0.011 ± 0.1556 |
| Week 25 | -0.049 ± 0.1797 | 0.014 ± 0.1518 |
| Week 31 | -0.023 ± 0.1619 | 0.013 ± 0.1665 |
| Week 37 | -0.035 ± 0.1505 | 0.013 ± 0.2234 |
| Week 43 | -0.046 ± 0.1360 | 0.058 ± 0.1990 |
| Week 49 | -0.100 ± 0.1796 | 0.026 ± 0.1936 |
| Week 55 | -0.164 ± 0.2056 | 0.028 ± 0.2067 |
| Week 61 | -0.091 ± 0.2229 | 0.031 ± 0.1364 |
| Week 67 | -0.076 ± 0.2347 | 0.039 ± 0.1954 |
| End Of Treatment | -0.125 ± 0.2432 | -0.138 ± 0.2461 |
| Safety Follow-Up | -0.062 ± 0.2391 | -0.099 ± 0.1942 |
EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.
| Millimeter | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Week 3/4 | 0.9 ± 13.94 | 0.6 ± 13.11 |
| Week 7 | -0.5 ± 13.59 | -2.1 ± 14.09 |
| Week 13 | -3.2 ± 12.83 | -0.7 ± 13.41 |
| Week 19 | -3.5 ± 16.39 | -0.1 ± 14.93 |
| Week 25 | -4.5 ± 15.66 | -1.4 ± 15.76 |
| Week 31 | -2.3 ± 13.14 | 1.4 ± 17.61 |
| Week 37 | -1.7 ± 11.78 | 0.9 ± 20.39 |
| Week 43 | -4.4 ± 11.92 | 3.2 ± 15.34 |
| Week 49 | -2.9 ± 8.95 | 2.1 ± 13.04 |
| Week 55 | -9.4 ± 16.32 | 3.4 ± 16.52 |
| Week 61 | -6.4 ± 18.09 | 3.5 ± 16.15 |
| Week 67 | -7.3 ± 17.10 | 4.9 ± 17.31 |
| End Of Treatment | -12.2 ± 22.39 | -10.3 ± 20.84 |
| Safety Follow-Up | -8.0 ± 19.24 | -9.6 ± 20.30 |
European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact. The EORTC QLQ-C30 GHS/QoL score ranges from 0 to 100; High score indicates better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.
| units on a scale | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Week 3/4 | 1.30 ± 15.486 | 0.85 ± 15.021 |
| Week 7 | -1.44 ± 14.905 | -1.01 ± 16.967 |
| Week 13 | -2.50 ± 15.424 | 0.24 ± 17.637 |
| Week 19 | -5.85 ± 18.363 | 1.37 ± 18.611 |
| Week 25 | -4.43 ± 15.407 | 0.41 ± 16.204 |
| Week 31 | -3.09 ± 19.902 | 1.85 ± 16.938 |
| Week 37 | -1.39 ± 22.186 | 1.77 ± 19.293 |
| Week 43 | -1.19 ± 12.167 | 3.33 ± 18.518 |
| Week 49 | 1.52 ± 9.731 | 4.01 ± 15.907 |
| Week 55 | 0.00 ± 11.785 | 4.00 ± 15.426 |
| Week 61 | -5.00 ± 13.944 | 2.38 ± 15.622 |
| Week 67 | 0.00 ± 9.129 | 4.90 ± 18.413 |
| End Of Treatment | -11.54 ± 23.460 | -11.67 ± 21.409 |
| Safety Follow-Up | -7.51 ± 19.475 | -9.29 ± 24.881 |
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) supplements the EORTC QLQ-C30 to assess symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, pain, reflux symptom, dietary restrictions, and anxiety) and 4 single items (dry mouth, hair loss, taste, body image). Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.
| units on a scale | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Dysphagia: Week 3/4 | 0.76 ± 13.371 | 0.60 ± 15.227 |
| Dysphagia Week 7 | 2.84 ± 15.258 | 1.34 ± 13.453 |
| Dysphagia Week 13 | 1.60 ± 14.090 | 0.65 ± 12.781 |
| Dysphagia Week 19 | -0.58 ± 15.772 | 1.52 ± 14.307 |
| Dysphagia Week 25 | -1.39 ± 10.465 | 1.69 ± 14.852 |
| Dysphagia Week 31 | 0.82 ± 14.755 | 4.39 ± 20.877 |
| Dysphagia Week 37 | -7.19 ± 17.977 | -0.67 ± 14.683 |
| Dysphagia Week 43 | -4.76 ± 14.265 | -2.59 ± 13.270 |
| Dysphagia Week 49 | -3.03 ± 8.736 | 1.23 ± 13.195 |
| Dysphagia Week 55 | 0.00 ± 13.608 | 0.89 ± 13.194 |
| Dysphagia Week 61 | 0.00 ± 15.713 | 1.06 ± 12.123 |
| Dysphagia Week 67 | -1.85 ± 10.924 | 1.31 ± 17.516 |
| Dysphagia End Of Treatment | 7.27 ± 25.134 | 8.21 ± 22.633 |
| Dysphagia Safety Follow-Up | 9.39 ± 21.467 | 7.25 ± 19.417 |
| Pain Week 3/4 | 1.51 ± 13.013 | -0.04 ± 13.465 |
| Pain Week 7 | 2.53 ± 15.351 | 2.60 ± 15.210 |
| Pain Week 13 | 2.96 ± 14.585 | 0.16 ± 13.523 |
| Pain Week 19 | 3.22 ± 14.152 | -0.51 ± 14.088 |
| Pain Week 25 | -1.56 ± 13.789 | -1.55 ± 17.540 |
| Pain Week 31 | 4.01 ± 19.111 | 0.97 ± 18.564 |
| Pain Week 37 | -4.90 ± 19.777 | -1.26 ± 12.346 |
| Pain Week 43 | 1.79 ± 18.251 | -1.94 ± 14.129 |
| Pain Week 49 | 1.52 ± 5.025 | -0.62 ± 12.853 |
| Pain Week 55 | 0.00 ± 19.543 | -1.00 ± 10.012 |
| Pain Week 61 | 3.33 ± 9.501 | -1.59 ± 13.596 |
| Pain Week 67 | 0.00 ± 12.910 | -0.49 ± 15.721 |
| Pain End Of Treatment | 9.25 ± 20.853 | 9.45 ± 22.960 |
| Pain Safety Follow-Up | 8.22 ± 18.011 | 10.99 ± 20.931 |
| Reflux Week 3/4 | 1.04 ± 14.197 | 0.12 ± 13.571 |
| Reflux Week 7 | 0.31 ± 14.695 | 0.50 ± 17.807 |
| Reflux Week 13 | 0.99 ± 14.098 | -1.09 ± 15.753 |
| Reflux Week 19 | 1.75 ± 17.032 | -1.68 ± 15.377 |
| Reflux Week 25 | 0.69 ± 14.648 | 1.69 ± 19.770 |
| Reflux Week 31 | -2.06 ± 14.791 | -1.29 ± 18.339 |
| Reflux Week 37 | -6.54 ± 18.864 | -4.38 ± 17.773 |
| Reflux Week 43 | -3.17 ± 15.364 | -5.56 ± 16.699 |
| Reflux Week 49 | 1.01 ± 9.236 | -2.06 ± 16.317 |
| Reflux Week 55 | 2.22 ± 4.969 | -3.56 ± 19.699 |
| Reflux Week 61 | 6.67 ± 9.938 | -6.35 ± 12.944 |
| Reflux Week 67 | 7.41 ± 13.456 | 0.00 ± 19.245 |
| Reflux End of Treatment | 3.43 ± 19.529 | 4.73 ± 20.455 |
| Reflux Safety Follow-up | 1.56 ± 20.254 | 2.90 ± 19.212 |
| Eating Restrictions Week 3/4 | 0.73 ± 16.279 | 0.13 ± 15.438 |
| Eating Restrictions Week 7 | 0.98 ± 16.123 | -0.27 ± 15.516 |
| Eating Restrictions Week 13 | 1.02 ± 14.234 | 0.00 ± 14.023 |
| Eating Restrictions Week 19 | -2.34 ± 16.648 | -0.63 ± 11.993 |
| Eating Restrictions Week 25 | -2.08 ± 18.208 | -1.55 ± 15.434 |
| Eating Restrictions Week 31 | -2.47 ± 15.814 | 0.39 ± 14.880 |
| Eating Restrictions Week 37 | -8.82 ± 21.943 | -3.28 ± 15.014 |
| Eating Restrictions Week 43 | -4.76 ± 18.115 | -3.89 ± 13.443 |
| Eating Restrictions Week 49 | 0.76 ± 11.459 | -5.25 ± 12.043 |
| Eating Restrictions Week 55 | 3.33 ± 15.138 | -6.00 ± 12.620 |
| Eating Restrictions Week 61 | 0.00 ± 15.590 | -5.56 ± 12.999 |
| Eating Restrictions Week 67 | 1.39 ± 13.351 | -2.45 ± 19.712 |
| Eating Restrictions EOT | 8.27 ± 20.898 | 10.01 ± 22.055 |
| Eating Restrictions Safety Follow-up | 7.04 ± 24.055 | 11.59 ± 25.050 |
| Anxiety Week 3/4 | -0.28 ± 16.150 | -4.06 ± 18.030 |
| Anxiety Week 7 | -1.30 ± 16.947 | -1.20 ± 20.580 |
| Anxiety Week 13 | -0.86 ± 20.685 | -2.83 ± 16.300 |
| Anxiety Week 19 | -1.56 ± 21.561 | -1.68 ± 19.220 |
| Anxiety Week 25 | -2.78 ± 23.780 | -1.69 ± 14.562 |
| Anxiety Week 31 | 4.12 ± 23.700 | -0.52 ± 24.119 |
| Anxiety Week 37 | -3.92 ± 20.765 | -1.01 ± 27.409 |
| Anxiety Week 43 | -3.97 ± 22.480 | -1.11 ± 24.474 |
| Anxiety Week 49 | 0.00 ± 12.172 | -6.17 ± 17.792 |
| Anxiety Week 55 | 2.22 ± 9.296 | -4.00 ± 20.000 |
| Anxiety Week 61 | -4.44 ± 12.669 | -4.76 ± 24.488 |
| Anxiety Week 67 | 9.26 ± 16.355 | -1.96 ± 24.918 |
| Anxiety End of Treatment | 4.58 ± 21.868 | 5.89 ± 23.939 |
| Anxiety Safety Follow-Up | 5.48 ± 24.116 | 4.99 ± 26.234 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.
| Participants | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Any TEAEs | 214 | 223 |
| Any Serious TEAE | 75 | 89 |
Blood samples were collected for the analysis of following hematology parameters: lymphocyte count, neutrophil count, white blood cells, platelet count, lipase, serum amylase, creatinine phosphokinase and creatinine. The hematology parameters were graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case (Grade 4) post Baseline is presented. Only those participants with increase to grade 4 have been presented.
| Participants | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| lymphocyte count decreased | 0 | 1 |
| neutrophil count decreased | 6 | 1 |
| white blood cells decreased | 2 | 0 |
| platelet count decreased | 1 | 0 |
| lipase increased | 6 | 8 |
| serum amylase increased | 3 | 2 |
| creatinine phosphokinase increased | 0 | 2 |
| creatinine increased | 0 | 1 |
Vital signs assessment included Systolic blood pressure (SBP), Diastolic blood pressure (DBP) and Pulse Rate (PR). Number of Participants with any potentially clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator.
| Participants | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Increased in Systolic blood pressure | 57 | 62 |
| Decreased in Systolic blood pressure | 43 | 69 |
| Increased in Diastolic blood pressure | 14 | 24 |
| Decreased in Diastolic blood pressure | 21 | 26 |
| Increased in pulse rate | 46 | 48 |
| Decreased in pulse rate | 32 | 30 |
ECG parameters included heart rate, pulse rate intervals, QRS interval, QT interval corrected based on Fridericia's formula (QTcF) intervals and QTcB intervals. Clinical significance was determined by the investigator. Number of participants with potentially clinically significant ECG abnormalities were reported.
| Participants | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Decreased heart rate | 0 | 1 |
| Increased heart rate | 2 | 2 |
| Increased Pulse Rate interval | 1 | 3 |
| Increased QRS interval | 5 | 8 |
| QTcF interval greater than (>)450milisecond (ms)less than or equal to(<=)480ms | 9 | 9 |
| QTcF interval: > 480 ms <= 500 ms | 2 | 3 |
| QTcF interval: > 500 ms | 3 | 1 |
| QTcB Interval: > 450 msec <= 480 msec | 19 | 18 |
| QTcB Interval: > 480 msec <= 500 msec | 2 | 2 |
| QTcB Interval: > 500 msec | 5 | 3 |
ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 5, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair, Grade 5 = Death. Number of participants with shift in ECOG PS Score to 1 or Higher Than 1 were reported.
| Participants | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Maintenance Phase: Number of Participants With Shift in Eastern Cooperative Oncology Group (ECOG) Performance Status Score to 1 or Higher Than 1 | 140 | 144 |
Collected over From randomization into maintenance phase up to 1276 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chemotherapy + Best Supportive Care (BSC) | 13/238 (5.5%) | 75/238 (31.5%) | 203/238 (85.3%) |
| Avelumab | 16/243 (6.6%) | 89/243 (36.6%) | 191/243 (78.6%) |
| Event | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| Disease progressionGeneral disorders | 6/238 | 14/243 |
| DysphagiaGastrointestinal disorders | 2/238 | 6/243 |
| VomitingGastrointestinal disorders | 4/238 | 4/243 |
| Obstruction gastricGastrointestinal disorders | 4/238 | 3/243 |
| Gastric haemorrhageGastrointestinal disorders | 4/238 | 0/243 |
| Decreased appetiteMetabolism and nutrition disorders | 4/238 | 4/243 |
| Abdominal painGastrointestinal disorders | 2/238 | 4/243 |
| PyrexiaGeneral disorders | 2/238 | 4/243 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/238 | 4/243 |
| AscitesGastrointestinal disorders | 3/238 | 3/243 |
| Event | Chemotherapy + Best Supportive Care (BSC) | Avelumab |
|---|---|---|
| NauseaGastrointestinal disorders | 52/238 | 41/243 |
| AnaemiaBlood and lymphatic system disorders | 48/238 | 35/243 |
| Peripheral sensory neuropathyNervous system disorders | 42/238 | 14/243 |
| Decreased appetiteMetabolism and nutrition disorders | 42/238 | 26/243 |
| DiarrhoeaGastrointestinal disorders | 39/238 | 27/243 |
| NeutropeniaBlood and lymphatic system disorders | 36/238 | 12/243 |
| Neutrophil count decreasedInvestigations | 35/238 | 4/243 |
| FatigueGeneral disorders | 29/238 | 35/243 |
| Platelet count decreasedInvestigations | 34/238 | 6/243 |
| ThrombocytopeniaBlood and lymphatic system disorders | 34/238 | 8/243 |
Full analysis set included all randomized participants included in treatment arm to which they were randomized.
| Age, Continuous(Years) | Chemotherapy + Best Supportive Care (BSC) | Avelumab | Total |
|---|---|---|---|
| Mean | 60.6 ± 11.70 | 60.7 ± 11.03 | 60.7 ± 11.36 |
| Sex: Female, Male(Participants) | Chemotherapy + Best Supportive Care (BSC) | Avelumab | Total |
|---|---|---|---|
| Female | 83 | 85 | 168 |
| Male | 167 | 164 | 331 |
| Ethnicity (NIH/OMB)(Participants) | Chemotherapy + Best Supportive Care (BSC) | Avelumab | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 19 | 34 |
| Not Hispanic or Latino | 213 | 220 | 433 |
| Unknown or Not Reported | 22 | 10 | 32 |
| Race/Ethnicity, Customized(Participants) | Chemotherapy + Best Supportive Care (BSC) | Avelumab | Total |
|---|---|---|---|
| White | 161 | 171 | 332 |
| Black or African American | 2 | 2 | 4 |
| Asian | 59 | 61 | 120 |
| American Indian or Alaska Native | 2 | 0 | 2 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| Not collected at this site | 22 | 12 | 34 |
| Other | 3 | 3 | 6 |
| Missing | 1 | 0 | 1 |
Showing the first 100 of 200 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Sep 2019, 44 months.
Results were first posted in Nov 2021, 2 years 1 month after primary completion. A results delay was requested in Oct 2019.
Of 83 industry-sponsored phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's 44 months is close to that.
Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Avelumab · Oxaliplatin · Fluorouracil · Leucovorin · Capecitabine
EMD Serono Research & Development Institute, Inc. →